{
  "pmcid": "7093794",
  "sha256": "1c30c0c50036f0bee90d1cb21ce10fb3ba9b477d92ffaefd834e4e33b27d8513",
  "timestamp_utc": "2025-11-09T22:53:22.695264+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.131947576958243,
    "reading_ease": 28.303474550441962,
    "word_count": 193
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of DACC-Coated vs. Alginate Dressings for Pilonidal Sinus Wound Healing"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "multicentre, open-label randomised controlled trial involved 246 patients"
      },
      "Participants": {
        "score": 2,
        "evidence": "246 patients undergoing pilonidal sinus surgery across four French hospitals"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive either DACC-coated or alginate dressings"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to compare wound healing using dialkylcarbamoyl chloride (DACC)-coated dressings versus alginate dressings."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the proportion of wounds healed at 75 days."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated with allocation concealment via telephone."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was not possible for patients or clinicians."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "246 patients undergoing pilonidal sinus surgery across four French hospitals from December 2013 to September 2017."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "In per-protocol analysis, 78 of 103 patients (75.7%) in the DACC group and 58 of 97 (60%) in the alginate group"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "odds ratio 2.55, 95% CI 1.12 to 5.92; P = 0.023"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events included severe pain, hyperglycaemia, pregnancy, and hyperalgic inflammatory granulation in the alginate group."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT02011802."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}